GRCL
Price:
$10.25
Market Cap:
$7.19B
Gracell Biotechnologies Inc., a clinical-stage biopharmaceutical company, primarily discovers and develops cell therapies for the treatment of cancer in the People's Republic of China. Its lead product candidates include GC012F, a FasTCAR-enabled dual BCMA- and CD19-directed autologous CAR-T product candidate that is in Phase I trial for the treatment of multiple myeloma; GC019F, a FasTCAR-enabled CD19-directed autologous CAR-T product candidate, which is in Phase I clinical trial for the treatment of adult B cell acute lymphoblastic leukemia (B-ALL), as well as in preclinical stage for the treatment of relapsed or refractory (r/r) B cell non-Hodgkin's lymphoma (B-NHL); and GC027, a TruUCAR-...[Read more]
Industry
Biotechnology
IPO Date
2021-01-08
Stock Exchange
NASDAQ
Ticker
GRCL
According to Gracell Biotechnologies Inc.’s latest financial reports and current stock price. The company's current Enterprise Value is 5.63B. This represents a change of 1.04% compared to the average of 494.28M of the last 4 quarters.
The mean historical Enterprise Value of Gracell Biotechnologies Inc. over the last ten years is 3.63B. The current 5.63B Enterprise Value has changed 15.39% with respect to the historical average. Over the past ten years (40 quarters), GRCL's Enterprise Value was at its highest in in the September 2020 quarter at 11.07B. The Enterprise Value was at its lowest in in the March 2022 quarter at -450925795.13.
Average
3.63B
Median
3.28B
Minimum
433.44M
Maximum
10.07B
Discovering the peaks and valleys of Gracell Biotechnologies Inc. Enterprise Value, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 206.75%
Maximum Annual Enterprise Value = 10.07B
Minimum Annual Increase = -91.56%
Minimum Annual Enterprise Value = 433.44M
Year | Enterprise Value | Change |
---|---|---|
2022 | 433.44M | -48.99% |
2021 | 849.68M | -91.56% |
2020 | 10.07B | 206.75% |
2019 | 3.28B | -7.27% |
The current Enterprise Value of Gracell Biotechnologies Inc. (GRCL) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages
3-year avg
3.78B
5-year avg
3.63B
10-year avg
3.63B
Gracell Biotechnologies Inc.’s Enterprise Value is greater than Theseus Pharmaceuticals, Inc. (138.26M), greater than Monte Rosa Therapeutics, Inc. (496.24M), greater than Design Therapeutics, Inc. (335.13M), greater than Erasca, Inc. (840.72M), greater than NextCure, Inc. (9.61M), greater than CytomX Therapeutics, Inc. (62.37M), greater than Neoleukin Therapeutics, Inc. (-6333315.00), greater than Spero Therapeutics, Inc. (-7881706.00), greater than Assembly Biosciences, Inc. (75.01M), greater than Terns Pharmaceuticals, Inc. (287.52M), greater than Amylyx Pharmaceuticals, Inc. (283.06M), greater than Acumen Pharmaceuticals, Inc. (126.58M), greater than Inozyme Pharma, Inc. (187.31M), greater than X4 Pharmaceuticals, Inc. (48.86M), greater than Bolt Biotherapeutics, Inc. (31.17M), greater than Coherus BioSciences, Inc. (329.80M), greater than Icosavax, Inc. (713.87M), greater than Day One Biopharmaceuticals, Inc. (966.48M), greater than Decibel Therapeutics, Inc. (102.82M), less than Blueprint Medicines Corporation (6.48B),
Company | Enterprise Value | Market cap |
---|---|---|
138.26M | $181.50M | |
496.24M | $578.12M | |
335.13M | $362.94M | |
840.72M | $856.66M | |
9.61M | $31.93M | |
62.37M | $92.35M | |
-6333315.00 | $8.20M | |
-7881706.00 | $63.79M | |
75.01M | $102.02M | |
287.52M | $556.35M | |
283.06M | $352.34M | |
126.58M | $129.77M | |
187.31M | $165.10M | |
48.86M | $68.06M | |
31.17M | $22.36M | |
329.80M | $195.86M | |
713.87M | $769.04M | |
966.48M | $1.39B | |
102.82M | $123.37M | |
6.48B | $6.10B |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Gracell Biotechnologies Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like Gracell Biotechnologies Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the Enterprise Value?
How can you use the Enterprise Value?
What is Gracell Biotechnologies Inc.'s Enterprise Value?
What is the highest Enterprise Value for Gracell Biotechnologies Inc. (GRCL)?
What is the 3-year average Enterprise Value for Gracell Biotechnologies Inc. (GRCL)?
What is the 5-year average Enterprise Value for Gracell Biotechnologies Inc. (GRCL)?
How does the current Enterprise Value for Gracell Biotechnologies Inc. (GRCL) compare to its historical average?